Previous news here:
Nexstim Initiates Multicenter Clinical Trial on the Therapeutic Effects of Navigated TMS for Stroke Rehabilitation
I'm sure this will be interesting because they are stimulating the good side.
Nexstim has launched a multicenter double-blinded, randomized, and
sham-controlled trial to determine the therapeutic effects of navigated
rTMS (repetitive transcranial magnetic stimulation) for stroke
rehabilitation. This cutting-edge stroke therapy combines occupational
therapy with nTMS (navigated transcranial magnetic stimulation).
https://globenewswire.com/news-release/2017/03/07/932688/0/en/Nexstim-Plc-Announces-the-Start-of-Patient-Enrolment-in-the-Supplementary-Phase-III-Trial-in-Stroke-Rehabilitation-with-its-NBT-system.htmlCompany announcement, Helsinki, 7 March 2017 at 11:30 am
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system (NBT® system), announces that it has enrolled the first patients in its supplemental Ph III clinical trial in stroke rehabilitation, known as E-FIT (ELECTRIC FIELD NAVIGATED 1HZ RTMS FOR POST-STROKE MOTOR RECOVERY TRIAL) at the Rancho Los Amigos National Rehabilitation Center, Downey, California, U.S.A.
As
previously announced, this clinical trial is designed to supplement the
completed Ph III NICHE trial. The supplemental trial will be conducted
at five clinical sites in the U.S.A. and will include a total of 60
subjects. All sites participating in E-FIT trial also participated in
the completed NICHE trial. Nexstim expects that the E-FIT trial to be
completed in Q1 2018 and to file for FDA clearance by end of April 2018.
FDA clearance would allow Nexstim to start marketing and selling its
NBT® system for stroke rehabilitation in the USA.
Commenting
on the enrolment of the first subjects, Charles Y. Liu, MD, PhD,
Professor of Neurological Surgery, Neurology, and Biomedical Engineering
and Director, USC Neurorestoration Center, the Principal Investigator
at the enrolling site, stated: "As the top enrolling site in the
previous NICHE trial, we are excited to participate in the E-FIT trial.
We are looking forward to the trial being completed and data analysed
together with the good outcomes seen in the NICHE trial."Commenting on the start of this trial, Jarmo Laine, Vice President Medical Affairs, Nexstim Plc stated: " The E-FIT trial preparations and start-up have gone extremely well. I am very pleased to report the rapid enrolment of clinical sites and our first trial subjects and we look forward to bringing the rehabilitation benefits that our NBT® system could deliver to stroke patients in the US in addition to Europe where we already have CE mark approval."
NEXSTIM PLC
Martin Jamieson, Chairman and CEO
Further information is available on the website www.nexstim.com or by telephone:Martin Jamieson, Chairman and CEO
Nexstim +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246
Citigate Dewe Rogerson +44 (0)207 2821066
Katja Stout katja.stout@citigatedr.co.uk
About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com
Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/9db29058-efc6-4aae-b2b7-78055bc70ec8Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com
No comments:
Post a Comment